Blueshift Asset Management’s Corcept Therapeutics CORT Stock Holding History

Blueshift Asset Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-16,957	Closed	-$382K	–	735
2022 Q1	$382K	Buy	+16,957	New	+$361K	0.03%	527
2021 Q4	–	Sell	-17,566	Closed	-$346K	–	907
2021 Q3	$346K	Sell	17,566 -12,257	-41%	-$257K	0.02%	763
2021 Q2	$656K	Buy	29,823 +12,641	+74%	+$281K	0.04%	475
2021 Q1	$409K	Buy	+17,182	New	+$459K	0.04%	540
2020 Q1	–	Sell	-26,668	Closed	-$323K	–	285
2019 Q4	$323K	Buy	+26,668	New	+$371K	0.04%	584

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blueshift Asset Management's CORT Position: Q2 2022 in Review

Blueshift Asset Management sold out of Corcept Therapeutics (CORT) in Q2 2022, closing a stake of 16,957 shares — an estimated $382K sold.

Blueshift Asset Management first reported a position in CORT in Q4 2019 and held it in 5 quarters. The position peaked at $656K in Q2 2021. 225 funds tracked by Wall St. Rank hold CORT as of Q2 2022.

Blueshift Asset Management reported no remaining Corcept Therapeutics position as of Q2 2022 after selling out during the quarter.
Blueshift Asset Management sold 16,957 Corcept Therapeutics shares in Q2 2022, an estimated $382K.
Blueshift Asset Management first reported a position in Corcept Therapeutics in Q4 2019 and held it in 5 quarters.
Blueshift Asset Management's Corcept Therapeutics position peaked at $656K in Q2 2021.
225 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2022.

Based on Blueshift Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.